TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02507375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab will be administered as intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab will be administered as intravenous (IV) infusion.
Study: NCT02126267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full mouth disinfection
Description: Procedures for scaling and root planing were performed in a single stage (24 hours) divided into two sessions (60 min per session) on two consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel and gluconate
Description: application of chlorhexidine (CX) (1%) gel in pockets after scaling, brushing tongue for 1 min. with CX (1%) gel and mouthwash at the beginning and end of each session with CX 0.2% for 30 seconds (with the form of a gargle in the last 10 seconds)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate solution
Description: Home use fo CX 0.2% for 60 consecutive days after the end of the first session of scaling.
Study: NCT01060592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoFLIP device (FDA Device Listing Number : D091203)
Description: The EndoFLIP balloon catheter will be introduced to the band and used to permit the band stoma size to be adjusted to 7mm.
Study: NCT01290939

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study: NCT02126267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate solution
Description: Home use fo CX 0.2% for 60 consecutive days after the end of the first session of scaling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin (500 mg) once daily for 3 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin (500 mg) once daily for 3 consecutive days.
Study: NCT02422966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study: NCT00976820

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340274A
Description: Two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340274A
Description: Two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340273A
Description: Two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340273A
Description: Two intramuscular injections
Study: NCT01290939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine
Study: NCT02531516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH (agonist)
Study: NCT01290939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lomustine
Study: NCT04321356

Intervention type: DEVICE
Intervention: Triathlon PCR TKA
Description: Total Knee Arthroplasty System
Study: NCT02531516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH (agonist)
Study: NCT04321356

Intervention type: DEVICE
Intervention: Triathlon PS TKA
Description: Total Knee Arthroplasty System

Intervention type: DEVICE
Intervention: Persona PCR TKA
Description: Total Knee Arthroplasty System

Intervention type: DEVICE
Intervention: Persona PS TKA
Description: Total Knee Arthroplasty System
Study: NCT02531516

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 74-80 Grays (units of radiation)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 74-80 Grays (units of radiation)
Study: NCT03443388

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hövding inflatable helmet
Description: The Hövding inflatable helmet is designed for cyclists as a collar with a deployable airbag that inflates when a sensor detects rapid changes in acceleration. The inflated helmet wraps the back and sides of the user's head in inflated nylon fabric which then slowly deflates after deploying.
Study: NCT04599192

Intervention type: OTHER
Intervention: No study intervention
Description: The study does not determine any interventions. Any intervention performed during coronary angiography is considered standard of care.
Study: NCT01252563

Intervention type: DRUG
Intervention: Amlodipine
Description: Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose. Dosage should be adjusted depending on the patient's symptoms. The dose can be raised up to 10 mg once daily for patients who show inadequate response.
Study: NCT05242913

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fully digestible corn starch
Study: NCT00946998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline is a serotonin-selective reuptake inhibitor (SSRI) used to treat major depression. Dosage will begin at 50 mg/d and will be escalated by 50 mg increments every 2 weeks to a maximum of 200 mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet will be identical and matched to sertraline tablet.
Study: NCT02055053

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.5% Bupivicaine
Description: Local anesthetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Bupivicaine
Description: Local anesthetic
Study: NCT01143298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 27847 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 27847 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 27847 oral solution
Study: NCT03609931

Intervention type: PROCEDURE
Intervention: Mitral Valve Model
Description: Creation of a mitral valve patient specific model to see if it mimics the patients valve
Study: NCT04080843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a capsule in the form of 500 mg, orally, 850 mg/m2, twice daily, 2 weeks on/1 week off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2,D1
Study: NCT00621166

Intervention type: DRUG
Group type: OTHER
Intervention: generic lopinavir/ritonavir
Description: Patients will start with lopinavir/ritonavir new formulation 400/100 mg bid with a low fat diet plus 2 nucleoside reverse transcriptase inhibitors (NRTIs). The choice of the 2 NRTIs is at the discretion of the investigator, though in general the use of zidovudine+lamivudine (300/150mg Combivir®) is recommended. If patients can be included at or before gestational week 20, a 12h pharmacokinetic curve will be recorded at week 20 (± 2 weeks)(Group 1). There should be a minimum of 2 weeks between start of lopinavir and pharmacokinetic recording. If they are included after week 20, the first 12h pharmacokinetic curve will be recorded at gestational week 33 (± 2 weeks)(Group 2). For the patients in both groups a 12 hr curve will be recorded.~Subjects in Group 1 will be offered to conduct a second 12h pharmacokinetic curve at week 20 (± 2 weeks), but this is only optional. Both groups will be asked to participate in the post partum curve, again this is optional.
Study: NCT00235014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trandolapril
Description: 2 mg QD
Study: NCT01290939

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: DNA methylation analysis
Study: NCT01998971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Administered by either intravenous or subcutaneous infusions, in combination with the applicable backbone treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Administered by either intravenous or subcutaneous infusions, in combination with the applicable backbone treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Administered by either intravenous or subcutaneous infusions, in combination with the applicable backbone treatment.
Study: NCT05832905

Intervention type: BEHAVIORAL
Intervention: Mobile and Wearable-assisted Case Management
Description: The MCM group received case management and Mobile-and wearable recording. The actual intervention for Panic disorder, including pharmacotherapy or psychological treatment is the same as in MCM and TAU group

Intervention type: BEHAVIORAL
Intervention: Mobile and Wearable-assisted Case Management
Description: The MCM group received case management and Mobile-and wearable recording. The actual intervention for Panic disorder, including pharmacotherapy or psychological treatment is the same as in MCM and TAU group
Study: NCT04310605

Intervention type: BEHAVIORAL
Intervention: CBT 1
Description: CBT for tinnitus (Step 1) comprised: individual audiometric assessment, and counselling about hearing and tinnitus (1hr) with an audiologist; a one-off educational group session (a max 10 participants and partners) (2hrs); an assessment session with a psychologists (1 hr).
Study: NCT01998971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Administered by either intravenous or subcutaneous infusions, in combination with the applicable backbone treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Administered by either intravenous or subcutaneous infusions, in combination with the applicable backbone treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Administered by either intravenous or subcutaneous infusions, in combination with the applicable backbone treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Administered subcutaneously in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Administered subcutaneously in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Administered subcutaneously in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Administered orally in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered intravenously or orally in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered intravenously or orally in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered intravenously or orally in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered intravenously or orally in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered intravenously or orally in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Administered orally in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered intravenously or orally in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Administered orally in accordance with product labeling and local standards.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Administered in prophylactic doses intravenously (or equivalent) in accordance with product labeling and local standards.
Study: NCT01290939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT04310605

Intervention type: BEHAVIORAL
Intervention: CBT 1
Description: CBT for tinnitus (Step 1) comprised: individual audiometric assessment, and counselling about hearing and tinnitus (1hr) with an audiologist; a one-off educational group session (a max 10 participants and partners) (2hrs); an assessment session with a psychologists (1 hr).

Intervention type: BEHAVIORAL
Intervention: CBT 2
Description: Step 2 group sessions were 2 hrs long over a 12-week period. Two therapists (a psychologist and physiotherapist) were present at any one time for Step 2 sessions. Step 2 included: psycho-education; exposure therapy; mindfulness exercises; cognitive restructuring; attention redirecting techniques; stress reduction; and, relaxation techniques. Evening sessions were also provided for participants to attend with family or partners.
Study: NCT01629290

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enamel Pro
Description: Varnish treatment containing 5% NaF

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duraphat
Description: Varnish treatment containing 5% NaF
Study: NCT01290939

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cognitive assessment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cognitive assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Study: NCT01150448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate Treatment A
Description: All patients will receive a single IM injection of 150mg eq of study drug on Day 1. Patients who tolerate 150mg eq will receive a 2nd IM injection of 150mg eq on Day 8 followed by 12 IM injections (1 every 4 weeks) of 150mg eq. All other patients will be assigned to Treatment B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate Treatment B
Description: Patients not tolerating Treatment A will receive a single IM injection of study drug 100mg eq at their next scheduled visit followed by injections (1 every 4 weeks) ranging from 50 to 150mg eq
Study: NCT02661126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3682B
Description: FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3682B
Description: FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3682B
Description: FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.
Study: NCT01629290

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vanish
Description: Varnish treatment containing 5% NaF

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bland varnish containing no NaF
Study: NCT01273623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jetstream Atherectomy System
Description: to perform atherectomy on calcified lesions
Study: NCT05660005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Stretching
Description: Stretching based on the FAIR (flexion, adduction and internal rotation) position, which provides the most effective stretching on the piriformis muscle, was demonstrated, and a illustrated brochure containing the explanatory information of the application was given to the group participants. With the ipsilateral hip flexion, adduction and internal rotation, the foot is positioned to the lateral side of the contralateral knee, thus long-term passive stretching is targeted in this position. Individuals were asked to leave a 2-days gap between the two stretching exercise sessions by performing 10 repetitions (minimum duration of 15 s stretching, 30 s rest period between repetitions) 3 sets and 3 days of a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self Myofascial Release
Description: The patient was presented with the anatomically localized area of the PiM on a visual anatomy map and they were encouraged to find this area on their body. They were asked to verify the trigger points along the PiM and then sat on the trigger points with the help of a tennis ball. Individuals were taught the PiM-SMR exercise, in which they would make forward-backward, right-left, diagonal and circular movements on the ball using their body weight. There was a continuation of the application with an interval of 2 days; 3 times a day with 10 repetitions (the application was for 1 min and 30s rest period between repetitions).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home exercises
Description: The exercise brochure consists of 5 different exercises that include isometric and isotonic strengthening of the hip and surrounding muscles. Isometric contraction of gluteus maximus, hip march, external/internal rotation of hips with theraband, 4 sided straight leg raises were the exercises and prescribed 5 days a week, 10 repetitions, 3 sets. All participants were advised to use analgesics determined by the physician in case of unbearable pain and to apply a hot pack for 10-20 minutes before sessions.
Study: NCT01998971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Administered in prophylactic doses intravenously (or equivalent) in accordance with product labeling and local standards.
Study: NCT01649141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy
Description: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) is a structured, 12-16 session outpatient intervention originally developed to treat Posttraumatic Stress Disorder (PTSD) and related emotional and behavioral difficulties in youth with a history of child sexual abuse. TF-CBT's eight components are delivered in 90-minute weekly sessions split evenly between children and their parents. These components are summarized by the acronym PRACTICE including: psychoeducation and parenting skills (P), relaxation (R), affective expression and regulation (A), cognitive coping (C), trauma narrative development and processing (T), in vivo gradual exposure (I), conjoint parent/child sessions (C) and enhancing safety and future development (E).
Study: NCT03270176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1143
Description: Debio 1143 100 to 250 mg, capsule orally for 10 days every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/kg intravenous infusion every 2 weeks.
Study: NCT02271555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthetic induction will be achieved via 8% sevoflurane

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: Anesthetic induction will be achieved via 8% sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: After the loss of consciousness saline will be administered to Group sevoflurane-saline intravenous bolus.
Study: NCT00991198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical oxygen
Description: 0.5% concentration of Topical oxygen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical oxygen
Description: 0.25% concentration topical oxygen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no O2
Study: NCT01901055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CPAP
Description: CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham-CPAP
Description: Sham-CPAP is a device that has a mask worn over the nose that is attached to a device that looks and sounds like CPAP however it does not provide positive airway pressure. Sham-CPAP is worn while sleeping, it does not splint open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Education
Description: Diabetes Education will be delivered to participants in both the CPAP group and the Sham-CPAP group. The education will be based on ADA and AADE guidelines and consist of 2 in-person sessions (90 minutes and 60 minutes) and 3 follow-up phone calls 9about 15 minutes each)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diabetes Education
Description: Diabetes Education will be delivered to participants in both the CPAP group and the Sham-CPAP group. The education will be based on ADA and AADE guidelines and consist of 2 in-person sessions (90 minutes and 60 minutes) and 3 follow-up phone calls 9about 15 minutes each)
Study: NCT01448135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VITAL AF
Description: Semi-elemental, high protein, and high omega-3 fish oil enteral formula